NYR's Principal Activity is the development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-36.01%|
|vs ASX 200 (1yr)||-39.73%|
Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company is in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. The Company's two lead programs centre on cholesterol-lowering and brain injury. The programs are focused on developing an oral, small molecule cholesterol-lowering drug, and a drug to treat secondary brain damage following a stroke or traumatic brain injury (TBI).
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Dr Ian Edward Dixon||Founder,Non-Executive Director||Sep 2020||
Dr Ian Edward Dixon
Mr Dixon, In 2011, Co-Founded Cynata Inc, a company that is progressing the commercialisation of what has become the Cymerus technology of ASX-listed Cynata Therapeutics Ltd (ASX-CYP). Dr Dixon is a co-inventor of the LEAP Technology owned by Exopharm. Dr Dixon brings to the Board a technical and entrepreneurial background in founding, building and running technology-based companies, in recognising the potential commercial value of early-stage drug development, and in understanding the challenges involved in drug development. Dr Dixon is also a founder of Exopharm Ltd. During the last three years, Dr Dixon has served as a director of the following listed companies: Medigard Ltd (ASX:MGZ) and Noxopharm Ltd (ASX:NOX
|Mr Christopher Cox||Non-Executive Director||Nov 2019||
Mr Christopher Cox
Mr Cox is a Co-Founder and Managing Partner of Population Health Partners, L.P., a global private equity firm focused on innovative therapeutics with the potential to transform health outcomes for populations. Prior to that, from January 2012 to February 2020, he was a partner at Cadwalader, Wickersham & Taft LLP, where he also served as the Chairman of Cadwalader's Corporate Department and as a member of its Management Committee. He remains a Senior Attorney of Cadwalader. From February 2016 to March 2019, Chris was seconded to The Medicines Company, a global biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was responsible for business development and strategy. Prior to January 2012, he was a partner at Cahill Gordon & Reindel LLP. He also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a private investment holding company with interests in life sciences, entertainment and technology
|Mr John Alexander Moore||Non-Executive Chairman,Non-Executive Director||Jun 2019||
Mr John Alexander Moore
Non-Executive Chairman,Non-Executive Director
Mr Moore currently serves as Chairman of Trialogics, a clinical trial informatics business and Chairman of Scientific Industries (SCND-OTCQB) a producer of laboratory instruments for the life sciences industry. He was CEO of Acorn Energy from 2006 to 2015, during which time the CoaLogix business was acquired for US$11 million and sold for US$101 million, and the Comverge business listed in the US before its sale to Constellation Energy. In 2002 he was a Partner and CEO of Edson Moore Healthcare Ventures and acquired for US$148 million a portfolio of sixteen drug delivery investments from Elan Pharmaceuticals.
|Mr Ruediger Weseloh||Non-Executive Director||Jun 2019||
Mr Ruediger Weseloh
Mr Weseloh is a Senior Director of Business Development at Merck KgaA, Darmstadt, Germany, where over a period of 15 years he has led more than 60 transactions for its pharmaceutical division, completing deals across the drug development value chain in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before Merck KgaA, Dr Weseloh spent 5 years as a Biotech/Pharma Equity Analyst at Gontard & Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen Dr Weseloh also serves on the Supervisory Board of Cytotools AG, Freiburg, German
|Mr Marcus Frampton||Non-Executive Director||Jun 2019||
Mr Marcus Frampton
Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC), the US$82 billion sovereign wealth fund for the State of Alaska. Mr Frampton manages the investment team at APFC and leads all investment decisions related to APFC's investment portfolio within the guidelines established by APFC's Board of Trustees. Before joining the APFC in 2012, Mr Frampton held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to private equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a private equity-backed portfolio company at LPL Financial (2010-2012). In addition to his duties at the APFC, Mr Frampton is also a shareholder and sits on the board of directors of Scientific Industries, Inc., a leading manufacturer of laboratory equipment and the owner of intellectual property related to bioprocessing systems
|Mr Peter Ashley Marks||Non-Executive Director||Aug 2017||
Mr Peter Ashley Marks
Mr Marks has over 35 years' experience in corporate advisory and investment banking. Throughout his long career, he has specialised in capital raising, IPOs, cross border M&A transactions, corporate underwriting, and venture capital transactions for companies in Australia, the US and Israel. He has been involved in a broad range of transactions with a special focus on the life sciences, biotechnology, medical technology and high-tech segments. He has served as both an Executive and Non-Executive Director of several different entities which have been listed on the ASX, NASDAQ, and AIM markets. He is currently a Director of Alterity Therapeutics Limited (ASX:ATH and NASDAQ:ATHE), Non-Executive Director of Noxopharm Limited (ASX: NOX) and Non-Executive Director of Elsight Ltd (ASX:ELS). Until 31 March 2020, he was also a Non-Executive Director of Fluence Corporation Ltd (ASX: FLC).
|Mr David James Franks||Company Secretary||N/A|
|Mr James Bonnar||Chief Executive Officer||N/A|
NYR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|02/03/21||John Moore||Buy||+19,000||$0.35||$6,650||On-market trade|
|02/03/21||John Moore||Buy||+500||$0.204||$102||As advised by the company|
|23/02/21||Marcus Frampton||Buy||+25,000||$0.357||$8,925||On-market trade|
|18/01/21||Ian Dixon||Issued||1,800,000||$0.40||$720,000||Director remuneration|
|25/11/20||John Moore||Buy||+32,000||$0.206||$6,600||On-market trade|
|24/11/20||Marcus Frampton||Buy||+35,000||$0.21||$7,350||On-market trade|
|10/09/20||John Moore||Buy||+32,500||$0.21||$6,825||On-market trade|
|23/04/20||John Moore||Buy||+35,000||$0.168||$5,882||On-market trade|
The current holdings of NYR directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
No Substantial Shareholders for NYR in our database.
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|29-06-21||Altnia Holdings Pty Ltd||192,308||7.16||6.48|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.